Episode
UBS Upgrades Jazz Pharmaceuticals, Bets on Ziihera
- Published
- May 23, 2026
- Duration seconds
- 137
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/durham-news-today-2-min-news-the-daily-news-now-7569659/episodes/ubs-upgrades-jazz-pharmaceuticals-bets-on-ziihera/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/durham-news-today-2-min-news-the-daily-news-now-7569659/ubs-upgrades-jazz-pharmaceuticals-bets-on-ziihera.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
UBS upgrades Jazz Pharmaceuticals to a buy, boosting price target by 63% to $307, anticipating Ziiheras commercial success and double-digit growth. Investors advised to be patient, start small, and consider adding more around the August FDA decision. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/6e96147d35bd0c12